CytomX Therapeutics, Inc.
650 Gateway Boulevard
Suite 125
South San Francisco
California
94080-7014
United States
Tel: 650-515-4987
Fax: 650-351-0353
Website: http://cytomx.com/
74 articles with CytomX Therapeutics, Inc.
-
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
7/9/2019
CytomX Therapeutics, Inc. announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates.
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional targets using CytomX’s Probody platform.
-
CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody™ Therapeutic Platform
2/26/2019
CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166, Demonstrates Encouraging Anti-Cancer Activity in Multiple Tumor Types and Safety in Phase 1 Dose Escalation
-
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
-
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
-
This week Pfizer notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration.
-
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
3/7/2018
Bristol-Myers Squibb acquisition of IFM Therapeutics, and Amgen-CytomX licensing deal recognized among more than 4,000 transactions in annual Cortellis Deal of the Year Awards from Clarivate Analytics
-
CytomX Therapeutics Added to NASDAQ Biotechnology Index
12/18/2017
CytomX Therapeutics today announced that the company has been added to the NASDAQ Biotechnology Index effective December 18th, 2017.
-
Medidata Expands Partnership With CytomX Therapeutics to Centralize Management of Regulated and Nonregulated Content
12/5/2017
With the addition of Medidata RCM, CytomX will now manage regulated and nonregulated content in a single, unified platform.
-
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 P...
11/28/2017
The IND acceptance results in a $10 million milestone payment to CytomX. -
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress
11/8/2017
As of September 30, 2017, CytomX had cash, cash equivalents and short-term investments of $331.3 million.
-
CytomX Therapeutics to Announce Third Quarter 2017 Financial Results
10/27/2017
The company will not conduct a conference call in conjunction with this financial results press release.
-
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors
10/25/2017
Dr. Fuchs is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development.
-
Biotech Giant Amgen Bets $1.5 Billion on Bay Area CytomX's Cancer Drugs
10/6/2017
-
Five Prime Adds Former CytomX-Genentech Immuno-Onco Vet To The Roster
8/18/2017
-
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call
8/8/2017
-
CytomX To Announce Second Quarter 2017 Financial Results And Provide Mid-Year Update
7/27/2017
-
CytomX Achieves Development Milestone In Strategic Oncology Collaboration With AbbVie For CD71-Targeting Probody Drug Conjugate
6/29/2017
-
CytomX Announces Management Team Changes
5/16/2017